Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Pharmaceutical industry news

Show

From To
Gilead's Sovaldi soars with sales of $3.48 billion

An excellent day for Gilead Sciences has seen the US biotech post record-breaking sales of its hepatitis C pill Sovaldi and approval in the USA for Zydelig to treat three types of blood cancer.

Published
25 July 2014
From
Pharma Times
US govt demands more pricing info on Gilead HCV pill

The cost of Gilead Sciences’ hepatitis C pill Sovaldi is once again under the spotlight with the US Senate Finance Committee requesting detailed pricing information.

Published
15 July 2014
From
Pharma Times
Obamacare's Surprising HIV Drug Demand

The Affordable Care Act has established basic core health requirements for insurance plans offered in the U.S. that support those diagnosed with life-threatening chronic diseases, including HIV. As a result, Express Scripts has reported that demand for drugs used to treat HIV and prevent HIV transmission grew in the first quarter because of rising enrollment in both marketplace plans and the expansion of Medicaid in many states.

Published
14 July 2014
From
Motley Fool
Zombie patents

Drug companies are adept at extending the lifespan of patents, at consumers’ expense

Published
25 June 2014
From
The Economist
HCV drug out of the running

The German pharmaceutical giant Boehringer Ingelheim is stopping development of faldaprevir, its hepatitis C virus (HCV) drug.

Published
23 June 2014
From
MedPage Today
A 4-week hep C cure? Bristol to test drugs with Gilead's Sovaldi

In the race to find a faster cure for hepatitis C, Bristol-Myers Squibb Co said it will test its experimental antiviral drug combination with Gilead Sciences Inc's blockbuster drug Sovaldi, hoping to cut treatment time to four weeks.

Published
23 June 2014
From
Reuters
UNITED STATES: FDA Approves AbbVie's Hepatitis C Regimen for Priority Review

The US Food and Drug Administration (FDA) has granted priority review for AbbVie’s experimental all-oral regimen for treating adults infected with hepatitis C virus (HCV). The drug’s application under priority review means that FDA must evaluate the safety and effectiveness of the AbbVie regimen within six months before letting the manufacturer know whether they may take the product to market. AbbVie’s new regimen consists of an antiviral called ritonavir and a protease inhibitor called ABT-450, combined with an NS5A inhibitor called ombitasvir and the polymerase inhibitor dasabuvir. When taken together, these mechanisms are powerful enough to stop HCV. [Article source: http://www.techtimes.com]

Published
19 June 2014
From
CDC
Dolutegravir in HIV-1 infection: Added benefit in adult patients

The German Institute for Quality and Efficiency in Health Care (IQWiG) has determined that the new integrase inhibitor drug dolutegravir (Tivicay ®) is of considerable added benefit to treatment-naive patients in comparison with current first-line therapies, and some added benefit to patients who already need to take an integrase inhibitor.

Published
19 June 2014
From
Science Daily
South Africa: Litigation threat may prompt access to cheaper DR-TB drug

South Africa may finally allow access to a cheaper form of the drug-resistant tuberculosis (DR-TB) drug linezolid following the lodging of a high court case.

Published
16 June 2014
From
Health-e
NICE consults on draft guidance on the drug sofosbuvir (Sovaldi) for treating hepatitis C

In draft recommendations published today healthcare guidance body NICE is asking Gilead Sciences for more information on its product sofosbuvir (Sovaldi), for the treatment of chronic hepatitis C. “The available evidence shows that sofosbuvir is an effective treatment for chronic hepatitis C in certain patients. However, evidence is lacking for some subgroups of patients with chronic hepatitis C, and there are also substantial uncertainties in the evidence base presented by the manufacturer.”

Published
16 June 2014
From
NICE press release
← First12345...66Next →

Filter by country